Ask AI
H.R. 5343

Ensuring Patient Access to Critical Breakthrough Products Act

A plain-language summary from the Congressional Research Service isn’t available yet for this bill. CRS summaries are typically posted within a few weeks of introduction.

Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.

Rep. Moore, Blake D. [R-UT-1](R-UT)Sponsor
51 cosponsors26 D25 R
51cosponsors2committees6actions7subjects
  1. Committee

    Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.

    Ways and Means Committee
  2. Committee

    Committee Consideration and Mark-up Session Held

    Ways and Means Committee
  3. IntroReferralH11100

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Energy and Commerce Committee
  4. IntroReferralH11100

    Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Ways and Means Committee
  5. IntroReferralIntro-H

    Introduced in House

  6. IntroReferral1000

    Introduced in House

Ensuring Patient Access to Critical Breakthrough Products Act — Informed